All posts tagged: biotech

French Startup Uses Special Polymers to Better Help Nerves Heal

French Startup Uses Special Polymers to Better Help Nerves Heal

Roughly 500,000 Americans suffer nerve injuries that require treatment each year, whether from an errant attempt to hack out an avocado pit or an unfortunate woodworking accident. Many will never get full feeling back in their fingers. But a startup has developed a thick and sticky liquid that could change that, and it’s begun deploying it with surgeons in the US. French firm Tissium is working to replace and supplement medical stitches with a liquid that attaches to tissue when exposed to light. A biopolymer made of fatty acid and glycerol—both of which naturally occur in the body—the liquid acts like a splint to hold the nerves in place while the tissue mends itself. It then biodegrades after the body heals, leaving nerves intact. Peripheral nerves make up the sprawling network of the nervous system, branching off from the brain and the spinal cord to the rest of the body. When one is cut, often through injuries involving knives or machinery, the two ends need to be held in place while the nerve slowly repairs …

3 People Have Gotten Cancer-Detecting Implants in Their Brains

3 People Have Gotten Cancer-Detecting Implants in Their Brains

A San Francisco startup with ties to Elon Musk’s Neuralink has started testing its brain implant to detect and treat cancer in humans. Coherence Neuro says it temporarily placed its coin-sized implant in the brains of three people undergoing surgery to have brain tumors removed at the Royal Melbourne Hospital in Australia. The implant was in place for roughly 30 minutes before being removed, providing an important safety check before the device can be implanted long-term in patients with brain cancer. Known as a brain-computer interface, the Coherence Neuro device is designed to sense the unique electrical signals of tumors and deliver mild electrical stimulation to prevent their growth. In the time the implant was in the patients’ brains, the company was able to see how it performed for a short period. (The patients had consented prior to surgery.) Matthew MacDougall, Neuralink’s head neurosurgeon, is an adviser and investor in Coherence. Rory Murphy, a neurosurgeon at the Barrow Neurological Institute in Arizona who is an investigator in one of Neuralink’s trials, is also slated to …

The Most Promising Ebola Vaccine Has Been Sitting on the Shelf for 15 Years

The Most Promising Ebola Vaccine Has Been Sitting on the Shelf for 15 Years

“We thought that’s probably the one that’s least likely to pop up,” Geisbert says. “We guessed wrong.” Concerned by that knowledge gap, in 2011 he decided to modify a vaccine, which led to the crab-eating macaque study. In the same study, he also finally tested a blend of existing ebola vaccines on the Bundibugyo strain, but they didn’t provide 100-percent protection. If the 2012 outbreak had occurred after the major Zaire outbreak, Geisbert says, it’s possible pharmaceutical companies might’ve been more keen to commercialize a vaccine that protects against the Bundibugyo strain. But with the present outbreak rivaling the 2013 to 2016 one in terms of scale and scope, efforts to play catch-up are going into high gear. Geisbert suspects WHO’s experience with Ervebo is one of the reasons they favor his vaccine candidate, which is basically “Bundibugyo Ervebo,” he says. WHO also noted the success of a similar rVSV-based vaccine targeting the Sudan strain of ebola in a ring vaccination trial in 2025. The rVSV-based Bundibugyo candidate’s suitability for ring vaccination was backed by …

What happens in Vega$: steroids, swimmers, and a billion-dollar hustle

What happens in Vega$: steroids, swimmers, and a billion-dollar hustle

I am sitting in the sweltering Nevada heat watching a man struggle to lift a bar over his head. If the man manages to do it, he will win $250,000. The man is Boady Santavy — a two-time Olympic weight-lifting contestant from Canada — and he has muscles that look culled from the Marvel Cinematic Universe: massive, cartoonish arms that might as well belong to a superhero rather than a real human. Santavy is attempting to beat the world record for the men’s snatch — a lift of 183 kilograms, or approximately 403 pounds. After a tortured few seconds, Santavy drops the bar — an official “no lift” — and, with a look of animated dismay on his face, hobbles away, visibly cursing. Santavy is one of a small horde of 42 athletic contestants — weight lifters, swimmers, and track runners — that have gathered in Las Vegas over Memorial Day weekend to compete in the Enhanced Games, a unique (and, by now, quite notorious) athletic competition in which almost all of the participating athletes are …

What happens in Vega$: steroids, swimmers, and a billion-dollar hustle

I went to the so-called ‘steroid Olympics,’ to understand why Silicon Valley is obsessed with peptides

I am sitting in the sweltering Nevada heat watching a man struggle to lift a bar over his head. If the man manages to do it, he will win $250,000. The man is Boady Santavy — a two-time Olympic weight-lifting contestant from Canada — and he has muscles that look culled from the Marvel Cinematic Universe: massive, cartoonish arms that might as well belong to a superhero rather than a real human. Santavy is attempting to beat the world record for the men’s snatch — a lift of 183 kilograms, or approximately 403 pounds. After a tortured few seconds, Santavy drops the bar — an official “no lift” — and, with a look of animated dismay on his face, hobbles away, visibly cursing. Santavy is one of a small horde of 42 athletic contestants — weight lifters, swimmers, and track runners — that have gathered in Las Vegas over Memorial Day weekend to compete in the Enhanced Games, a unique (and, by now, quite notorious) athletic competition in which almost all of the participating athletes are …

Small biotech firms quicker to ‘latch onto’ AI than big ones, says Tencent Healthcare President

Small biotech firms quicker to ‘latch onto’ AI than big ones, says Tencent Healthcare President

HONG KONG, May 28 : Small biotech firms “latch onto” AI more quickly than bigger firms, the head of Chinese tech giant Tencent’s healthcare division said on Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk and Eli Lilly have announced AI-related collaborations with technology firms. “When you have less people, when you need to do more, you tend to figure out more efficient ways of doing things,” Tencent Healthcare President Alex Ng told Reuters. “AI is definitely something that they latch onto very quickly,” he said. For very big pharmaceutical companies, however, with elaborate organisation and specified workflows, just adding an AI will sometimes not be successful, Ng said. Industry forecasts suggest that the use of machine learning to optimize target discovery, design molecules and streamline clinical trial planning could halve early-stage development timelines and costs within …

This young startup is taking on a fragrance industry that hasn’t changed in a almost half century

This young startup is taking on a fragrance industry that hasn’t changed in a almost half century

Fragrance tech company Patina says it has raised $2 million in funding investors, including Betaworks and True Ventures.  The company focuses on creating new scent molecules using advanced molecular design, machine learning, and scent research. Today, most of the scent molecules used in consumer products are created by a small number of specialized labs, which then sell those molecules to fragrance houses or cosmetics companies — the brands that ultimately turn them into perfumes, candles, or flavored products. Patina is trying to shake that up, entering an area that has seen little innovation in the past half century. The company was founded by Sean Raspet and Laura Sisson. Raspet is an artist and perfumer who, over time, developed an obsession with human senses and began creating new scent and flavor molecules as a creative pursuit. Sisson, meanwhile, came from a background in food and software engineering, and became obsessed with human senses after discovering an entire scientific field dedicated to modeling them. The two met, naturally, at a scent art gallery in New York in …

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Google DeepMind’s AlphaFold has already revolutionized scientists’ understanding of proteins. Now, the ability of the platform to design safe and effective drugs is about to be put to the test. Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize–winning AI technology. “We’re gearing up to go into the clinic,” Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. “It’s going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.” Jaderberg did not elaborate on the timeline, but it’s later than the company had planned to initiate human studies. Last year, CEO Demis Hassabis said it would have AI-designed drugs in clinical trials by the end of 2025. Isomorphic Labs was founded in 2021 as a spinoff from Alphabet’s AI research subsidiary, Google DeepMind. The company uses DeepMind’s AlphaFold, a groundbreaking AI platform that predicts protein structures, for drug discovery. Built from 20 different amino acids, proteins are …

Designer Baby Companies Are in Turmoil

Designer Baby Companies Are in Turmoil

Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict. One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers in October that included a prominent fertility doctor, a data scientist who worked for de-extinction company Colossal Biosciences, and a scientist who pioneered a “three-parent” IVF technique. The other, California-based Bootstrap Bio, said it ceased operations in late 2025, as first reported by Mother Jones. Manhattan Genomics and Bootstrap Bio had ambitions to edit DNA in human embryos with the goal of preventing serious disease in babies. Known as germline editing, the idea is highly controversial because any changes made at the embryo level would be passed on to future generations. It’s different from gene-editing treatments currently being tested on patients, which only affect the treated individual. The safety and efficacy of germline editing is also unproven. One concern is that the technology can result in unintended, potentially harmful “off-target” edits. Many researchers worry that …

A Startup Says It Grew Human Sperm in a Lab—and Used It to Make Embryos

A Startup Says It Grew Human Sperm in a Lab—and Used It to Make Embryos

The goal, he says, is to create thousands of sperm from a standard tissue biopsy. The company has had a high success rate in generating sperm from dozens of tissue samples. Pastuszak says early testing shows the lab-made sperm look “effectively identical” to naturally made sperm. The procedure is not yet ready to be used to start pregnancies, though. Paterna created embryos as an early test to validate that its lab-made sperm was actually viable. The company plans to conduct a larger, more comprehensive study involving men with infertility. Paterna will extract sperm from their ejaculate or testicular tissue and use its method to generate sperm for the men. From there, the company will use both the extracted sperm and lab-made sperm to fertilize eggs in the lab, compare fertilization rates between the two groups, and analyze the resulting embryos for physical and genetic abnormalities. “That will actually tell us a ton regarding the efficacy and safety of the approach. It will tell us if there are any mutations that are created by the in …